O'Connor et al report results of a randomized trial of 7,141 people with acute decompensated heart failure who got nesiritide or placebo in addition to standard care. To sum up, nesiritide didn't seem to do much of anything at all (for dyspnea, risk of rehospitalization or death, or any other endpoint). NEJM 2011;365:32-43.